FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Barat Stephen		 2. Date of Event Requiring Statement (MM/DD/YYYY)
2/2/2023 

 3. Issuer Name and Ticker or Trading Symbol

HTG MOLECULAR DIAGNOSTICS, INC [HTGM]
(Last)        (First)        (Middle)

C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Senior VP of Therapeutics /
(Street)

TUCSON, AZ 85706      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 1361 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)11/8/2031 Common Stock 4166 $62.41 D  
Stock Option (right to buy)  (2)8/17/2032 Common Stock 2083 $11.28 D  
Explanation of Responses:
(1) 1/4th of the shares vested on the one-year anniversary of October 1, 2021 (the "Vesting Commencement Date"); the balance of the shares vest in a series of twelve (12) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occurring after the one-year anniversary of the Vesting Commencement Date.
(2) The shares vest in a series of eight (8) successive equal quarterly installments on the last day of each calendar quarter, with the first such installment occurring on September 30, 2022.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Barat Stephen
C/O HTG MOLECULAR DIAGNOSTICS, INC.
3430 E. GLOBAL LOOP
TUCSON, AZ 85706

Senior VP of Therapeutics
Signatures
/s/ Shaun D. McMeans, Attorney-in-Fact2/10/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more HTG Molecular Diagnostics Charts.
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more HTG Molecular Diagnostics Charts.